Evidence map›Paper›PMID 30214035›Full record

ArticleProstate cancer and prostatic diseases2019

Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data.

Chang Wook Jeong, Minyong Kang, Seung Il Jung, Tae-Hwan Kim, Sung Woo Park, Jae Young Joung, Seong Soo Jeon, Jun Hyuk Hong, Ji Youl Lee, Byung Ha Chung and 4 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Chang Wook JeongDepartment of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Minyong KangDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Seung Il JungDepartment of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, South Korea.
Tae-Hwan KimDepartment of Urology, Kyungpook National University School of Medicine, Daegu, South Korea.
Sung Woo ParkDepartment of Urology, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Jae Young JoungCenter for Prostate Cancer, National Cancer Center, Goyang, South Korea.
Seong Soo JeonDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jun Hyuk HongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Ji Youl LeeDepartment of Urology, St. Mary Hospital, Catholic University College of Medicine, Seoul, South Korea.
Byung Ha ChungDepartment of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Hanjong AhnDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Choung-Soo KimDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Dong Deuk KwonDepartment of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, South Korea.
Cheol KwakDepartment of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. mdrafael@snu.ac.kr.
Asan Medical Center · KRChonnam National University Hwasun Hospital · KRSeoul National University Hospital · KRSungkyunkwan University · KRGangnam Severance Hospital · KRKyungpook National University · KRNational Cancer Center · KRPusan National University Yangsan Hospital · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEnzalutamide can significantly prolong the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is a paucity of evidence on continuing androgen-deprivation therapy (ADT) for mCRPC. Here, we analyzed the effect of concomitant ADT during enzalutamide treatment in men with mCRPC following chemotherapy.

methodsWe retrospectively reviewed the medical records of 232 patients with mCRPC who received oral enzalutamide (160 mg per day) following chemotherapy at 9 tertiary centers in Korea between 2014 and 2016. The primary endpoint was overall survival, while secondary endpoints included time to prostate-specific antigen (PSA) progression and radiographic progression-free survival.

resultsThe median age of the patients was 71 years (interquartile range, 64-75 years). The proportion of patients in a grade group ≥4 was 77.6%. The rate of concomitant ADT was 29.3%, and the all-cause mortality rate was 27.1% (n = 63). Median overall survival, time to PSA progression, and radiographic progression-free survival were 24.0, 8.0, and 10.0 months, respectively. Notably, concomitant ADT showed a significant association with longer overall survival (median duration not reached vs. 18.2 months; p = 0.008). After adjusting for confounding factors, concomitant ADT was still associated with longer overall survival (hazard ratio, 0.35; 95% confidence interval, 0.17-0.72).

conclusionConcomitant ADT during enzalutamide treatment may improve the survival of patients with mCRPC following chemotherapy.

Indexed as

AgedAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingNitrilesPhenylthiohydantoinProportional Hazards ModelsProstatic Neoplasms, Castration-ResistantRetreatmentRetrospective StudiesAndrogen AntagonistsBenzamidesenzalutamideNitrilesPhenylthiohydantoin

Identifiers

PMID30214035
OpenAlexW2890018574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.